197 related articles for article (PubMed ID: 30463939)
1. Inhibition of ezrin causes PKCα-mediated internalization of erbb2/HER2 tyrosine kinase in breast cancer cells.
Jeong J; Choi J; Kim W; Dann P; Takyar F; Gefter JV; Friedman PA; Wysolmerski JJ
J Biol Chem; 2019 Jan; 294(3):887-901. PubMed ID: 30463939
[TBL] [Abstract][Full Text] [Related]
2. The scaffolding protein NHERF1 regulates the stability and activity of the tyrosine kinase HER2.
Jeong J; VanHouten JN; Kim W; Dann P; Sullivan C; Choi J; Sneddon WB; Friedman PA; Wysolmerski JJ
J Biol Chem; 2017 Apr; 292(16):6555-6568. PubMed ID: 28235801
[TBL] [Abstract][Full Text] [Related]
3. PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer.
Jeong J; VanHouten JN; Dann P; Kim W; Sullivan C; Yu H; Liotta L; Espina V; Stern DF; Friedman PA; Wysolmerski JJ
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E282-90. PubMed ID: 26729871
[TBL] [Abstract][Full Text] [Related]
4. HER2 signaling regulates HER2 localization and membrane retention.
Jeong J; Kim W; Kim LK; VanHouten J; Wysolmerski JJ
PLoS One; 2017; 12(4):e0174849. PubMed ID: 28369073
[TBL] [Abstract][Full Text] [Related]
5. NHERF1 Is Required for Localization of PMCA2 and Suppression of Early Involution in the Female Lactating Mammary Gland.
Jeong J; Kim W; Hens J; Dann P; Schedin P; Friedman PA; Wysolmerski JJ
Endocrinology; 2019 Aug; 160(8):1797-1810. PubMed ID: 31087002
[TBL] [Abstract][Full Text] [Related]
6. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
[TBL] [Abstract][Full Text] [Related]
7. MAL2 mediates the formation of stable HER2 signaling complexes within lipid raft-rich membrane protrusions in breast cancer cells.
Jeong J; Shin JH; Li W; Hong JY; Lim J; Hwang JY; Chung JJ; Yan Q; Liu Y; Choi J; Wysolmerski J
Cell Rep; 2021 Dec; 37(13):110160. PubMed ID: 34965434
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
9. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.
Lee H; Saini N; Howard EW; Parris AB; Ma Z; Zhao Q; Zhao M; Liu B; Edgerton SM; Thor AD; Yang X
Sci Rep; 2018 May; 8(1):6829. PubMed ID: 29717218
[TBL] [Abstract][Full Text] [Related]
10. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
11. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
[TBL] [Abstract][Full Text] [Related]
12. LASP-1 interacts with ErbB2 in ovarian cancer cells.
Sidhanth C; Bindhya S; Shabna A; Krishnapriya S; Manasa P; Nagare RP; Joshua T; Sneha S; Murhekar K; Ganesan TS
Biochem J; 2022 Jan; 479(1):23-38. PubMed ID: 34881777
[TBL] [Abstract][Full Text] [Related]
13. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
14. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
15. Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification.
Magnifico A; Albano L; Campaner S; Campiglio M; Pilotti S; Ménard S; Tagliabue E
Cancer Res; 2007 Jun; 67(11):5308-17. PubMed ID: 17545611
[TBL] [Abstract][Full Text] [Related]
16. FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.
Francis RE; Myatt SS; Krol J; Hartman J; Peck B; McGovern UB; Wang J; Guest SK; Filipovic A; Gojis O; Palmieri C; Peston D; Shousha S; Yu Q; Sicinski P; Coombes RC; Lam EW
Int J Oncol; 2009 Jul; 35(1):57-68. PubMed ID: 19513552
[TBL] [Abstract][Full Text] [Related]
17. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
[TBL] [Abstract][Full Text] [Related]
18. Regulation of ErbB2 localization and function in breast cancer cells by ERM proteins.
Asp N; Kvalvaag A; Sandvig K; Pust S
Oncotarget; 2016 May; 7(18):25443-60. PubMed ID: 27029001
[TBL] [Abstract][Full Text] [Related]
19. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
20. Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
Ding J; Yao Y; Huang G; Wang X; Yi J; Zhang N; Liu C; Wang K; Zhang Y; Wang M; Liu P; Ye M; Li M; Cheng H
Cancer Lett; 2020 Apr; 475():53-64. PubMed ID: 32006616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
